Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
4 hedge funds and large institutions have $38.7K invested in Aptose Biosciences, Inc. in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
3% less capital invested
Capital invested by funds: $40K → $38.7K (-$1.27K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSC
Caldwell Sutter Capital
Sausalito,
California
|
+$324 |
Top Sellers
APTO Hedge Fund Activity: Q2 2026 in Review
4 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q2 2026, worth a combined $38.7K — down 3.2% from $40K a quarter earlier.
Fund positioning in APTO was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Caldwell Sutter Capital, adding an estimated $324.
- 4 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $38.7K of Aptose Biosciences, Inc. stock for Q2 2026, down 3.2% quarter-over-quarter.
- 0 funds opened new Aptose Biosciences, Inc. positions in Q2 2026 and 0 closed out.
- The largest Aptose Biosciences, Inc. buyer in Q2 2026 was Caldwell Sutter Capital, an estimated $324 added.
Based on aggregated 13F filings for Q2 2026.